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Abstract
Background: The causes of autism likely involve genetic and environmental factors that influence neurobiological
changes and the neurological and behavioral features of the disorder. Immune factors and inflammation are
hypothesized pathogenic influences, but have not been examined longitudinally.
Methods: In a cohort of 104 participants with autism, we performed an assessment of immune mediators such as
cytokines, chemokines, or growth factors in serum and cerebrospinal fluid (n = 67) to determine potential influences
of such mediators in autism.
Results: As compared with 54 typically developing controls, we found no evidence of differences in the blood
profile of immune mediators supportive of active systemic inflammation mechanisms in participants with autism.
Some modulators of immune function (e.g., EGF and soluble CD40 ligand) were increased in the autism group;
however, no evidence of group differences in traditional markers of active inflammation (e.g., IL-6, TNFα, IL-1β) were
observed in the serum. Further, within-subject stability (measured by estimated intraclass correlations) of most
analytes was low, indicating that a single measurement is not a reliable prospective indicator of concentration for
most analytes. Additionally, in participants with autism, there was little correspondence between the blood and CSF
profiles of cytokines, chemokines, and growth factors, suggesting that peripheral markers may not optimally reflect
the immune status of the central nervous system. Although the relatively high fraction of intrathecal production of
selected chemokines involved in monocyte/microglia function may suggest a possible relationship with the
homeostatic role of microglia, control data are needed for further interpretation of its relevance in autism.
Conclusions: These longitudinal observations fail to provide support for the hypothesized role of disturbances in
the expression of circulating cytokines and chemokines as an indicator of systemic inflammation in autism.
ClinicalTrials.gov, NCT00298246.
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Background
Autism spectrum disorder (ASD) is a lifelong neurodeve-
lopmental disorder found in up to 1% of the US popula-
tion [1], characterized by social communication deficits
and restricted and repetitive behaviors [2]. Risk for ASD is
highly associated with genetic factors [3], but current evi-
dence suggests that neurobiological abnormalities in ASD
are associated with changes in cytoarchitectural and neur-
onal organization that may be determined by the complex
interplay of genetic, environmental, and immunological
mechanisms [4–7]. Although ASD is not a classical
immune-mediated disorder, there is increasing interest in
examining the role of the immune system and inflamma-
tion in the development and persistence of the complex
neurological and behavioral abnormalities associated with
ASD [8–10].
Both innate and adaptive branches of the immune system
are involved in critical mechanisms of brain development,
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neuronal and cortical organization, developmental and
adaptive synaptic plasticity, and critical stages of brain func-
tion that determine neurological and behavioral activity
into adulthood [11]. From fetal development to adulthood,
the immune system and central nervous system (CNS) es-
tablish interactions which can influence both systemic im-
mune responses (peripheral immune system) and local
CNS immune function (neuroimmunity). Several lines of
research have revealed abnormalities in the interactions of
the immune system and CNS in ASD which involve distur-
bances in both adaptive and innate immunity [4, 6, 12, 13].
Evidence from the effects of maternal viral infections
during pregnancy [14], an excess of autoimmune disor-
ders in mothers of subjects with ASD or their families
[15, 16], and the effects of environmental factors on the
formation of the immune system [17] support the view
that various types of disturbances of immune function
play roles in the pathogenesis of ASD and the perpetu-
ation of associated behavioral and neurological abnor-
malities. Studies of immune function in ASD frequently
have focused on functional and quantitative studies of T
cells and B cells, antibody production, and the presence
of autoantibodies against neuronal epitopes. Studies of
cellular immunity found abnormal function and number
of T cells, as well as a lower percentage of CD4 T cells
and a skewed CD4:CD8 T cell ratio [9]. However, these
studies involved small samples, and more recent studies
have demonstrated altered function in selected immune
pathways and cell systems such as T regulatory cells and
NK cells in subjects with ASD [18–20].
An emerging theme centers on the role of cytokines
and chemokines, immune mediators which play important
roles in pro-inflammatory or anti-inflammatory responses
in the periphery and CNS. Cytokines and chemokines play
important immune, homeostatic, and regulatory roles in
the microenvironment of specific tissues or systems as
well as circulating blood and immune cell populations
[21–24]. Measures of circulating immune mediators or
the rate of production by specific immune cell populations
under specific conditions have been used for assessment
of immune reactivity status including pro-inflammatory
stages during disease. Although measurement of specific
cytokines or chemokines lack specificity to define disease,
their profiles and spectrum of expression may help to
understand pathogenic mechanisms of disease in which
the immune system may be involved [25–30]. Interest-
ingly, cytokines and chemokines also may facilitate pro-
cesses of immune-CNS interactions which modulate not
only inflammatory responses within the CNS but also
neuroimmune mechanisms associated with neuronal
homeostasis, synaptic plasticity, and neuroglial function
[31]. However, the literature is inconsistent in that no sin-
gle marker is found to be abnormal consistently across
studies. The majority of existing studies in ASD
characterized cytokine and chemokine profiles in the
plasma or serum [32], and each study finds a different
profile of differences between children with ASD and chil-
dren with developmental delay or typical development,
most commonly elevations in ASD [33–36].
Fewer studies have examined the CNS directly,
through the cerebrospinal fluid (CSF) or brain tissues;
Vargas and colleagues [37] found increased levels of pro-
inflammatory and modulatory cytokines, differentially
expressed across the cortical regions in post-mortem
samples from individuals with ASD. The goal of this
study was to provide data testing the hypothesis that
children with ASD differ in immune profile, especially in
pro-inflammatory markers, from those without ASD.
Given the importance of determining the role of
immune-CNS interactions in ASD, the current study
was designed to longitudinally assess immune mediators
in children with ASD compared to children with typical
development by focusing on the expression profile of
cytokine and chemokine networks in the peripheral im-
mune compartment (serum), to determine the pattern of
expression of such immune mediators in the neuroim-
mune system compartment represented by CSF and to




Participants were drawn from a longitudinal study of
autism (NCT00298246) implemented at the National In-
stitute of Mental Health/NIH, Bethesda, Maryland. A
legal guardian provided written consent for participation
in this NIH Combined Neurosciences Institutional Re-
view Board-approved study (06-M-0102). In the autism
group (AUT), autistic disorder was diagnosed using
DSM-IV-TR [38] criteria by a team of doctoral-level ex-
perienced clinicians, using the Autism Diagnostic
Interview-Revised [39], Autism Diagnostic Observation
Schedule [40], and clinical judgment. Typically develop-
ing controls (TYP) were recruited for lack of concern in
any domain of development and were screened using
the Social Communication Questionnaire [41] and cog-
nitive testing. The groups were not matched on cogni-
tive function, and correlation between immune profile
and clinical characteristics was outside the scope of the
current report. All children in the current study were
between the ages of 2 and 7.99 at baseline and were
followed at intervals of approximately one year, for up to
3 years. Per study design, serum samples were collected
from subjects up to four times at intervals to approxi-
mately 1 year, and CSF samples were collected once (at
baseline) or twice (at final visit, if possible).
Medical history related to immune status (i.e., allergies,
immunodeficiency, autoimmune disorder) was collected
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for both groups of children via structured interview with
medical personnel. For members of the AUT group who
underwent lumbar puncture, serum was collected con-
temporaneously with CSF, under sedation, following a 12-
hour fasting period. All CSF and blood samples (including
those collected in the absence of lumbar puncture) were
collected during the morning period (9 am–12 noon). Eth-
ical constraints prevented lumbar punctures in the TYP
group, so none of the TYP serum samples were collected
under sedation. CSF was immediately centrifuged after the
LP procedure, and acellular aliquots were stored at −70 °C
within 20–30 min. Serum samples were collected follow-
ing standard procedures and aliquoted and stored within
20–30 min after separation. Up to four serum samples
and up to two CSF samples were obtained from partici-
pants, at intervals ranging from 9–24 months, and stored
until simultaneous laboratory analysis.
Assay technique
We used multiplexed bead assay techniques for estab-
lishing the profiles of 39 immune mediator proteins that
included cytokines, chemokines, and growth factors in
serum and CSF. The selected panel was the most compre-
hensive available. Assay reagents and plates were obtained
from well-validated commercial sources (Millipore®) [42].
The procedures followed recommendations and well-
established protocols for evaluation of serum [42, 43] and
the CSF [44, 45]. Only the first freeze-thaw aliquots were
used for assay measurements. To achieve uniformity in
the longitudinal assessment, assays for samples collected
at different timepoints from the same individual were run
simultaneously. Masked samples were measured in dupli-
cates and blank values subtracted from all readings. Mea-
surements and data analysis of all assays were performed
with the Luminex-200® system in combination with Lumi-
nex manager software (Bioplex manager 5.0, Bio-Rad,
Hercules, CA). We used standard operating procedures to
guarantee the consistency, reproducibility, and reliability
of the assays. Samples that exhibited unexpected or
unacceptable variance (i.e., evidence of bead clumping,
coefficients of variation greater than 20%, or unusual
distributions of values) were re-tested.
Statistical analysis
Serum Data analysis was performed in SAS/STAT
Version 9.3 [46] (PROC MIXED or PROC GLIMMIX).
The design of this analysis was roughly accelerated lon-
gitudinal case-control, which allows the study of change
over a long interval of age by gathering data over
shorter, variable periods of time, from participants with
baselines staggered across the age range of interest.
Modern statistical methods, particularly those that
utilize maximum likelihood estimation, are well-suited
to analyzing these data. Mixed models with restricted
maximum likelihood estimation are commonly used for
longitudinal data [47], using chronological age as the
time metric (rather than time point), and refer to the
“mixed” use of random and fixed effects. In this case,
the models included a random intercept, which accounts
for the correlation resulting from the up to four samples
within the same subject during study participation. Each
of the models also included several fixed effects, which
were sex, diagnosis, and chronological age. The best-
fitting model from those evaluating quadratic change
with age, linear change with age, or no change with age
was selected. We then considered the main effect of
diagnosis (i.e., does the mean level of the analyte differ
between groups?), and in the case of quadratic or linear
change models, the interaction of diagnosis and age (i.e.,
does the difference between diagnoses depend on age?).
Raw p values were used at the model-fitting stage of
analysis to find the best candidate model, but false dis-
covery rate (FDR; [48]) adjusted p values were used to
determine final statistical significance (<.05) and are
reported.
Within-subject estimates of stability in serum concen-
trations were obtained using the ratio of variance ex-
plained by the subject cluster to the total variance,
controlling for age, and replacing out-of-range values
with the limit of detection in order to provide the most
conservative estimate. These estimated intraclass correl-
ation coefficients (ICCs) range from 0 to 1 and are inter-
preted as standard correlation coefficients (i.e., values
from .60 to .80 are considered moderate, ≥.80 are con-
sidered strong).
Concentrations were transformed with a natural loga-
rithm, and values outside the range of detection were set
to missing. Variables with more than 30% out-of-range
values were analyzed as categorical (detected versus
not), in which case the generalized linear mixed model
with binomial distribution and a logit link function was
implemented in the strategy described above.
Finally, although the use of maximum likelihood esti-
mation to address missing data is commonplace, we
conducted sensitivity analyses in which the out-of-range
values were imputed with the limit of detection (e.g., all
out-of-range EGF values were replaced with 2.7 pg/mL)
and all variables were treated as continuous.
CSF CSF was available only for a subset of the AUT,
and two samples were obtained for a minority of partici-
pants. Therefore, change over time in CSF was not mod-
eled with mixed models of change in the analyte across
the age range, but instead, general stability estimates
(correlation) for sample 1 and sample 2 (controlling for
age and time-to-follow-up) were generated. For analytes
with an overall rate of out-of-range values less than 30%,
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partial Spearman’s correlations were used, and logistic
regression was used for variables with high out-of-range
rates. The relationship between circulating and CSF
levels of the immune modulators was assessed by calcu-
lating the fraction of intrathecal production (also called
percentage transfer), which is the ratio of CSF concen-
tration of a specific protein (immune mediator) to serum
concentration (percentage transfer = [Immune media-
torCSF/immune mediatorSerum] × 100). A fraction of
intrathecal production value greater than 100% indicates
higher levels of production within the CNS relative to
the periphery compartment; conversely, values less than
100% suggest the analyte production is mostly in the
periphery with minimal production within the CNS [49].
Finally, the Spearman correlation between serum and
CSF values were calculated, as it is possible that analytes
with rates of production that differ between compart-
ments may still be correlated.
Results
Participants were 104 children diagnosed with DSM-IV-
TR Autistic Disorder (AUT) and 54 typically developing
controls (TYP), aged 2–7.99 years at initial evaluation
(Table 1). Serum samples were obtained in all AUT and
TYP subjects while CSF was obtained in 67 AUT sub-
jects. No participant had a history of immunodeficiency
or autoimmune disorder. Food, environmental, and sea-
sonal allergies were present in a minority of participants,
but were more common in AUT (n = 36, 35%) than in
TYP (n = 10, 19%) (χ2 = 4.46, p = .03). Basic peripheral
blood and immune features (i.e., white blood cell count,
IgG, IgM, IgA) did not differ between groups (Additional
file 1: Table S1). Basic composition of the CSF appeared
normal; white blood cell count was normal, and the CSF
to serum albumin concentration quotient, which is an
index of blood-CSF barrier integrity, was within age-
adjusted expectations [50].
Serum immune mediators
Descriptive data for each of the serum immune mediators
are presented in Additional file 1: Table S2A and S2B.
Thirty of 39 analytes were analyzed as continuous vari-
ables; the remaining had 30% or more values outside the
range of detection and were analyzed as categorical vari-
ables (detected versus not detected). Results of the
mixed models are presented in Table 2; variables ana-
lyzed as categorical are denoted with a superscript a.
This table is interpreted as follows: the effect of age is
shown in the Age or Age2 column, depending on which
was the best-fitting model according to the uncorrected
p values. For linear or quadratic trends with uncorrected
p values <.05, between-group differences in slope were
tested with a contrast statement (none were significant,
p values are not reported). Evidence for linear change
over age (the Age column of Table 2) was found in
IL12p40, TNFα, and CCL22 (MDC); the general trend
was for a decrease in the analyte across ages 2 to 8 years,
and these patterns did not differ between groups (i.e.,
the Contrast statements were non-significant). There
was no evidence for change over age in the remaining
analytes.
The Group column reflects the test of whether a mean
difference existed between groups. A significant mean
difference between groups (the Group column in Table 2)
was observed on EGF (AUT > TYP, Cohen’s d = 0.44,
95% CI = 0.11–0.77), and a significant difference in odds
of out-of-range values was observed for sCD40L (OR =
3.40, 95% CI = 1.82–6.33; AUT was more likely to be
above the range of detection than TYP). Neither of these
effects was diminished when history of allergies, body
mass index, or platelet count was added to the model.
No significant differences in other analytes were
observed.
Results of the sensitivity analyses, wherein out-of-
range values were imputed at the limit of detection and
all variables were assessed as continuous, were consist-
ent with the primary analysis (data available upon
request).
Generally, the estimated ICC values for serum were
low, indicating a lack of within-subject stability (Fig. 1).
ICC values ranged from .19 (sCD40L) to .73 (CCL3/
MIP-1α), but most fell well below .60 (the median value
was .45). Both analytes found to differ, on average, be-
tween groups had low ICC (sCD40L, ICC = .19; EGF,
ICC = .27).
CSF immune mediators
Descriptive data for each of the CSF immune mediators
are presented in Additional file 1: Table S3. Unlike
serum, repeated CSF samples were available for a minor-
ity of participants (n = 31). Rather than modeling change
over age as was done in serum, we calculated the correl-
ation between CSF sample 1 and sample 2, controlling
for age (M± SD = 3.51 ± 0.95 years) and time-to-follow-
up (M± SD = 2.44 ± 0.68 years, range 1.17 to 3.53 years).
Sample 1 values were significantly related to sample 2
values for most analytes (Table 3). The rate of out-of-
range values for sample 2 given an out-of-range value
for sample 1 ranged from 50–100%.
Fraction of intrathecal production rates were observed
at both extremes (sCD40L, median 0.0008%; FLT-3L,
median 22,000%) (Fig. 2). The vast majority of analytes
had fraction of intrathecal production rates less than
100%, indicating relatively low CNS production com-
pared to serum. With a few exceptions, correlations
between serum and CSF values were low or non-
significant, further indicating little relationship between
the compartments (Additional file 1: Table S4).
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Discussion
The present study describes a comprehensive longitu-
dinal study of serum and CSF profiles of immune media-
tors and modulators in children with ASD. Three key
points emerge from these data. First, we used rare, longi-
tudinal CSF sampling to demonstrate striking differences
in the expression of selected cytokines, immune-related
growth factors, and chemokines in the CSF compart-
ment compared to the circulating bloodstream compart-
ment. These findings are consistent with data from
other populations [51], which show that peripheral
immune-related proteins do not mirror the neuroim-
mune and CNS microenvironment. Second, we used
these unique longitudinal data to demonstrate the limi-
tations of cross-sectional data. Although our analyses
revealed few developmental trends in circulating periph-
eral immune-related proteins during childhood, we
noted a striking lack of within-subject stability in most
of the analytes. The low ICC estimates obtained in this
study indicate that a single measurement is not a reliable
Table 1 Participant demographic characteristics (for sample 1)
Full sample Subsample with CSF
AUT TYP AUT
N 104 54 67
Male, n (%) 86 (83) 41 (76) 55 (82)
Race, n (%)
Black 20 (19) 4 (7) 12 (18)
Asian 4 (4) 0 3 (5)
White 74 (71) 44 (81) 47 (70)
Multiple races 5 (5) 5 (9) 4 (6)
Unknown 1 (1) 1 (2) 1 (2)
Ethnicity, n (%)
Hispanic 7 (7) 4 (7) 4 (6)
Non-Hispanic 97 (93) 49 (90) 63 (94)
Unknown 0 1 (2) 0
Age, M± SD 4.41 ± 1.27 3.64 ± 1.11 3.60 ± 0.95
Full scale DQ, M± SD 50.49 ± 18.04 109.91 ± 12.90 53.42 ± 16.32
Body mass index 16.68 ± 2.21 16.53 ± 1.42 16.52 ± 1.51
Number of samples, n (%)
1 104 (100%) 54 (100%) 67 (100%)
2 82 (78) 32 (59) 31 (46)
3 37 (36) 25 (46) –
4 11 (11) 6 (11) –
Parent reported immunologic historya, n (%)
None 68 (65) 44 (81) 43 (64)
Allergies (food, environmental, seasonal) 36 (35) 10 (19) 24 (36)
Immunodeficiency or autoimmune disorder 0 0 0
Serum basic features, M± SD
WBC count 8.15 ± 2.31 7.16 ± 1.73 8.42 ± 2.37
IgG, mg/dL 838.07 ± 251.71 760.94 ± 188.37 774.52 ± 252.22
IgM, mg/dL 83.95 ± 35.52 84.89 ± 33.78 80.73 ± 37.48
IgA, mg/dL 88.05 ± 51.82 86.81 ± 46.77 78.48 ± 46.26
CSF basic features, M± SD
WBC count – – 0.79 ± 1.03
Albumin quotient – – 2.62 ± 1.60
Data missing for two participants in each group.
Note: Sample size differed slightly for basic laboratory features. Serum WBC count: AUT, n = 101; TYP, n = 52. Serum IgG/IgM/IgA: AUT, n = 95; TYP, n = 52. CSF WBC
count, n = 63. CSF albumin quotient: n = 61. Body mass index sample size was AUT (serum), n = 85; TYP, n = 47; AUT (CSF), n = 64
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longitudinal indicator of a child’s level of most of serum
immune mediators and modulators we studied. Third,
we found no evidence for major differences in the
expression of circulating cytokines and chemokines
between children with autism and typically developing
controls. The results of our study do not support the hy-
pothesis that an active systemic inflammatory process
plays a role in the persistence of autistic disorder and
suggest that previously observed increases in brain tissue
cytokines and chemokines [37, 52] may reflect homeo-
static non-inflammatory roles in response to CNS dys-
function [10].
An overview of basic immune parameters such as
leukocyte count and profile of circulating immunoglobu-
lins revealed no differences between AUT and TYP. In
the peripheral immune system, as reflected by the circu-
lating bloodstream, only proteins with both immune
modulation and growth factor functions (EGF and
sCD40L) were significantly elevated longitudinally in
AUT compared to TYP. These differences occurred in
the absence of within-subject stability, suggesting that
while there was significant within-subject variability, the
general range of values observed in AUT differed from
that of TYP across timepoints.
Interestingly, proteins such as TNF-α, IL-6, and IFNγ
and chemokines such as CCL2 and CXCL10, frequently
associated with pro-inflammatory responses, did not differ
between AUT and TYP. The group differences observed
in two of the 39 analytes tested in this study, elevated
circulating EGF and sCD40L, could be construed as sug-
gesting that dysregulation of growth and modulatory path-
ways, rather than systemic inflammatory responses, may
occur in autism. In the periphery, both EGF and sCD40L
are carried by platelets and involved in mechanisms of tis-
sue repair, vascular function, and immune modulation
[53]. EGF is a growth factor that plays critical roles in the
growth, proliferation, and differentiation of numerous cell
types [54, 55], and is involved in several pathways of neur-
onal function and trophism [55, 56]. The results of the
current study are consistent with other comparisons of
serum EGF between children with and without autism.
Using enzyme-linked immunosorbent assay (ELISA), one
study documented significantly elevated serum EGF in 27
Turkish children with autism aged 2–11 years relative to
age-matched typical controls [57]. A second report, using
multiplex bead assay, found elevated serum EGF in 77
children and adolescents with autism (aged 5–15) com-
pared to 19 healthy, slightly older, controls [35]. However,
some studies have documented decreased EGF in the
plasma of subjects with autism compared to controls
[58–60]. These conflicting results may be related to
the type of sample used for the assays, as serum as-
says reflect all growth factors released by platelets
during the blood sampling processing for obtaining
serum [53]. It is worth noting that in the current
study, group differences remained when platelet count
was added to the model, though platelet count was
not available for all TYP participants.
Similar to EGF, the CD40 system plays a regulatory
role in the immune and vascular systems. sCD40L
modulates function of B cells including stimulation of
activation-associated surface antigen, immunoglobulin
isotype switching, immunoglobulin secretion, and
lymphocyte memory generation. The interaction of
sCD40L with its receptor, CD40, also plays important
function in monocyte activation and dendritic cell
Fig. 1 Estimated intraclass correlations (ICC) for each variable. The estimated ICC was obtained using the ratio of variance explained by the subject
cluster to the total variance, controlling for age (out-of-range values were replaced with the limit of detection). Lower values indicate less variance
explained by subject cluster, or less within-subject correlation or stability. By convention, values above .60 are considered moderate and above .80 are
considered strong
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Table 3 Estimated stability of CSF immune mediators in children with autism, controlling for age and time-to-follow-up
Partial Spearman correlations for variables with <30% outside the LOD % <LOD for one
or both samples
Rate of sample 2 <LOD
where sample 1 <LOD
n Partial correlation, 95% CI p value
Cytokines
IL-1A 26 .33 (−.09–.64) .11 16 1/5 (20%)
IL-IRA 87 21/25 (84%)
IL-1B 87 23/27 (85%)
IL-2 84 20/23 (87%)
sIL-2RA 65 15/17 (88%)
IL-3 52 15/15 (100%)
IL-4 97 29/29 (100%)
IL-5 28 .85 (.68–.93) <.0001 10 1/3 (33%)
IL-6 94 28/29 (97%)
IL-7 71 19/19 (100%)
IL-9 31 .82 (.63–.91) <.0001 0 na
IL-10 35 8/11 (73%)
IL-12p40 61 13/19 (68%)
IL-12p70 94 24/25 (96%)
IL-13 100 30/31 (97%)
IL-15 31 .80 (.61–.90) <.0001 0 na
IL-17 94 27/28 (96%)
IFNα2 30 .74 (.50–.87) <.0001 3 0/1 (0%)
IFNγ 68 16/18 (89%)
TNFα 31 .62 (.32–.80) .004 0 na
TNFβ 65 12/16 (75%)
TGFα 31 .84 (.67–.92) <.0001 0 na
Growth factors
EGF 100 31/31 (100%)
G-CSF 31 .53 (.19–.75) .003 0 na
GM-CSF 31 .72 (.48–.86) <.0001 0 na
VEGF 97 26/29 (90%)
FGF-2 74 17/21 (81%)
FLT-3L 31 .82 (.64–.91) <.0001 0 na
sCD40L 27 .63 (.30–.82) .0008 13 1/4 (25%)
Chemokines
CCL2 (MCP-1) 31 .64 (.35–.81) .0002 0 na
CCL3 (MIP-1α) 58 9/13 (69%)
CCL4 (MIP-1β) 48 12/12 (100%)
CCL7 (MCP-3) 71 12/19 (63%)
CCL11 (EOTAXIN) 97 26/30 (87%)
CCL22 (MDC) 32 5/10 (50%)
CXCL1 (GRO) 29 .53 (.18–.75) .004 6 0/2 (0%)
CXCL8 (IL-8) 31 .51 (.17–.74) .004 0 na
CXCL10 (IP-10) 31 .50 (.16–.73) .01 0 na
CX3CL1 (FRACTALKINE) 31 .42 (.06–.68) .02 0 na
Note: <LOD = below the lower limit of detection; na = not applicable. No restrictions were placed on time-to-follow-up for inclusion in these analyses. Mean age
for sample 1 was 3.51 ± 0.95 years; mean time-to-follow-up was 2.44 ± 0.68 years. Spearman’s correlation was calculated where at least 70% of the sample had
detectable values at both visits. Listwise deletion was used in correlation analyses; thus, individuals with out-of-range values were excluded. Age at sample 1 and
time-to-follow-up were partialled out in correlation analyses. Variables with high rates of values outside the range of detection were analyzed as categorical;
because of the small sample size and complete or quasi-complete separation, it was not possible to calculate reliable odds ratio estimates for these variables
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maturation [61]. No data exist regarding sCD40L in
ASD, though one relevant study documented decreasing
levels of sCD40L in healthy individuals across neonatal,
childhood, and adult age groups [62]. We found no
changes in sCD40L levels across childhood, but high rates
of out-of-range values may have obscured any develop-
mental trend. The second study, comparing children with
Prader-Willi syndrome to healthy siblings, found no sig-
nificant difference between the groups in plasma sCD40L,
though the trend was for higher values in the syndromic
children [63]. There are several studies documenting ele-
vated levels of sCD40L in adult psychiatric and health
conditions, where a negative relationship between sCD40L
and cognitive function has been demonstrated [64, 65].
Thus, the significance of the elevated blood circulating
levels of EGF and sCD40L in our participants with autism
remains unknown, especially given the high degree of
within-subject variability in concentration. Future investi-
gations could determine whether they influence the
spectrum of CNS, neurobehavioral, and cognitive dysfunc-
tion in subjects with ASD, but the variable nature of these
analytes dictates that this should be done only with
extreme caution, in longitudinal samples, and with appro-
priate controls to demonstrate the specificity to ASD (ra-
ther than for general developmental disability, for
example). One hypothesis is that genetically determined
growth or immune-modulatory dysregulation, rather than
active systemic inflammatory responses, is responsible for
elevated EGF and sCD40L. Previous SNP analyses of
growth factor genes revealed a haplotypic association of
EGF with ASD [66], suggesting that genetic factors may
cause elevated EGF levels. An alternative hypothesis is
that growth pathway dysregulation during early devel-
opment pre-established a context of elevated EGF.
However, our findings of low stability over time of
EGF (and most other analytes) necessitate caution in
considering an immune endophenotype.
A major finding of the present study is the lack of cor-
respondence in the profiles of circulating immune-
related modulators in the blood and CSF of participants
with ASD. This incongruence highlights essential differ-
ences in the CNS/neuroimmune and peripheral immune
system environments [67, 68]. Importantly, EGF and
sCD40L, the two serum analytes on which AUT and
Fig. 2 Relative concentrations and percent transfer (CSF:Serum) in AUT group with contemporaneous CSF and serum samples (n = 54). a The
relative ln-transformed concentration of analytes (labeled in the Y axis of (b)) in CSF versus serum. b The median percent transfer (with interquartile
range, IQR) for each analyte. For ease of presentation, Y axis units in (b) are log10. Values outside the range of detection were imputed with the limit of
detection. Percent transfer values of 100% (gray horizontal line) reflect equal CNS and serum production
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TYP differed, had extremely low fraction of intrathecal
production rates, indicating that peripheral activity had
little bearing on central presence of these analytes. The
relatively high levels and increased fraction of intrathecal
production of immune mediators such as FLT3L, IL-15,
CX3CL1, CXCL8, and CCL2 likely reflect the specific
production of these mediators by neuroglia or neuronal
cell populations in the CNS environment. The CSF profile
of these immune mediators likely reflects a homeostatic
role, as most of them have selective function on microglia
and the neuroglia-neuronal interactions required for
maintaining CNS homeostasis. For example, FLT3L pro-
motes cell differentiation, proliferation, and survival and
influence in the function of microglia cells in the CNS.
Similarly, CX3CL1 and CCL2, chemokines that facilitate
migration of monocytes to areas of injury, are critical for
monocytes physiology and migration and play critical
roles in the homeostatic function of microglia [69–71].
Interestingly, IL-15, a widespread expressed cytokine
which is involved in multiple signaling pathways in the
CNS of neurogenesis and neuroplasticity, is also a potent
microglia modulator [72–74]. These observations suggest
that the CNS environment in our population of subjects
with ASD was enhanced in favor of microglia function ra-
ther than other adaptive neuroinflammatory responses,
perhaps in response to a persistent stage of developmental
synaptic plasticity or neurodevelopmental processes in the
brain of these subjects [75].
Although this study focused on the assessment of im-
mune mediators in the blood and CSF compartments,
these results do not totally preclude the possibility that
systemic immune factors or inflammation may influence
brain development and alter neurobiological trajectories
and subsequent long-term neurobehavioral changes.
Such effects may only be observable when the immune
markers are derived from specific microenvironment
niches, or when they result from specific immune cell
populations in response to exogenous challenges (e.g.,
isolated PBMC [76]). In those cases, the immune
response is highly influenced by genetic determinants of
the host, but its relevance to pathogenesis of autism re-
mains uncertain. Regardless, the within-subject stability
should be considered in future explorations of non-CSF
compartment individual markers or profiles of these
markers, as the high degree of variability of most
analytes necessitates caution in interpreting single ob-
servations as an indicator of an enduring endopheno-
type. In addition, although CSF analyses permit a
more direct window into the physiological status of
the CNS than do peripheral measures, even they are
not capable of providing information about neuroim-
mune responses occurring in selected areas of the
brain, as has been demonstrated in previous studies
of brain tissues [37].
One limitation of this study was the lack of compari-
son data for the CSF, as ethical constraints on lumbar
punctures for healthy children precluded a comparison
group in the present study. Little is known about po-
tential differences between children and adults in CSF
concentrations of immune mediators; still, comparison
to adult samples may be helpful for context. AUT
CSF concentrations of the six immune mediators with
the highest percent transfer were similar to that of
the healthy adults and more dissimilar to adults with
active neuroinflammatory disorders, analyzed in the
same lab (Additional file 1: Figure S1). A second limi-
tation of this study, which we protected against by
correcting for the false detection rate, was the large
number of comparisons which may lead to spurious
results. A third limitation was the detection limits of
the assays, and high rates of out-of-range values in
several cases required us to model the proportion
out-of-range rather than the mean value. It is worth
noting that a difference in rate of out-of-range values
is similar to, but not the same as, a difference in
mean values. This type of dichotomization does re-
duce the power of a statistical test to detect relation-
ships, and assays with different sensitivities may have
produced different results. Finally, although the ma-
jority of participants contributed at least two serum
samples to the longitudinal analysis, it is possible that
the degree of data missingness may have influenced
the results.
Conclusions
In conclusion, this is the first longitudinal study of the
profile of serum immune mediators in children with
ASD compared to controls. The large sample size and
repeated measures design of this study are significant
strengths, as the power to detect differences between
groups is increased when error variance due to individ-
ual differences is reduced. Further, we explicitly modeled
the potential confounding effects of age in this sample,
which spanned from 2–8 years, and reduced the risk
spurious results due to age-related differences in im-
mune profiles. We also utilized groups matched on sex,
and controlled for sex in our statistical model, given
some data suggesting that males and females respond
differently to in utero inflammation [77]. Finally, this is
the only longitudinal study of chemokines and cytokines
in the CSF of children with ASD. These data provide im-
portant information about the lack of relationship be-
tween central and peripheral immune markers, signaling
that caution should be taken when interpreting the avail-
able studies implicating current immune dysfunction in
the phenomenology of ASD, as few have included direct
measures of CNS status.
Pardo et al. Molecular Autism  (2017) 8:1 Page 11 of 14
Additional file
Additional file 1: Table S1. Basic laboratory features. Table S2. Serum
descriptive data by age bands and diagnostic group. Table S3. CSF
descriptive data by age cohort. Table S4. Correspondence between
serum and CSF values in AUT sample (n = 54). Figure S1. Profile of
selected CSF immune mediators in AUT and two adult comparison
groups, median values and interquartile range. (DOCX 209 kb)
Abbreviations
ASD: Autism spectrum disorder; AUT: Autism study group; CNS: Central
nervous system; CSF: Cerebrospinal fluid; LP: Lumbar puncture; TYP: Typically
developing study group
Acknowledgements
The authors thank the many families who participated in this research. We
thank Deanna Greenstein, Ph.D. (NIMH) for the statistical consultation. The
views expressed in this paper do not necessarily represent the views of the
NIMH, NIH, HHS, or the United States Government. Protocol number 06-M-0102
and NCT00298246.
Funding
This work was supported by the Intramural Research Program (ZIA
MH002914) of the National Institute of Mental Health of the National
Institutes of Health, and the Pardo lab is supported by the Bart McLean
Fund for Neuroimmunology Research and Johns Hopkins Project Restore.
Availability of data and materials
The datasets generated during and/or analyzed during this study will be
available in the National Database for Autism Research (https://ndar.nih.gov);
until that time, the datasets will be available from the corresponding author
on reasonable request.
Authors’ contributions
CP contributed to the conception and design of this analysis and to the
acquisition and interpretation of the data, and helped to draft the manuscript.
CF devised and performed the statistical analysis of the data and helped to
draft the manuscript. AT contributed to the conception and design of the
study, the collection of patient data, and helped to draft the manuscript. FS
helped to devise and perform the statistical analysis of the data. JI contributed
to the acquisition and interpretation of the data. SK contributed to the
interpretation of the data. SS contributed to the conception and design of the
study. All authors read, commented upon, and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
A legal guardian provided written consent for participation in this NIH
Combined Neurosciences Institutional Review Board-approved study.
Author details
1Johns Hopkins University School of Medicine, 627 Pathology Bld., 6000
North Wolfe Street, Baltimore, MD 21287, USA. 2Pediatrics and
Developmental Neuroscience, National Institute of Mental Health, Bethesda,
MD, USA. 3Yale School of Public Health, Yale University, New Haven, CT, USA.
Received: 1 July 2016 Accepted: 14 December 2016
References
1. Developmental DMNSY, Investigators P. Prevalence of autism spectrum
disorder among children aged 8 years-autism and developmental
disabilities monitoring network, 11 sites, United States, 2010. Morb Mortal
Wkly Rep Surveill Summ (Washington, DC: 2002). 2014;63:1.
2. American Psychiatric Association. Diagnostic and statistical manual of
mental disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013.
3. Robinson EB, Neale BM, Hyman SE. Genetic research in autism spectrum
disorders. Curr Opin Pediatr. 2015;27:685–91.
4. Voineagu I, Wang X, Johnston P, Lowe JK, Tian Y, Horvath S, Mill J, Cantor
RM, Blencowe BJ, Geschwind DH. Transcriptomic analysis of autistic brain
reveals convergent molecular pathology. Nature. 2011;474:380–4.
5. Werling DM, Geschwind DH. Recurrence rates provide evidence for
sex-differential, familial genetic liability for autism spectrum disorders in
multiplex families and twins. Mol Autism. 2015;6:27.
6. Gupta S, Ellis SE, Ashar FN, Moes A, Bader JS, Zhan J, West AB, Arking DE.
Transcriptome analysis reveals dysregulation of innate immune response
genes and neuronal activity-dependent genes in autism. Nat Commun.
2014;5:5748.
7. Geschwind DH, State MW. Gene hunting in autism spectrum disorder: on
the path to precision medicine. Lancet Neurol. 2015;14(11):1109–1120.
8. Pardo CA, Eberhart CG. The neurobiology of autism. Brain Pathol. 2007;17:434–47.
9. Mead J, Ashwood P. Evidence supporting an altered immune response in
ASD. Immunol Lett. 2015;163:49–55.
10. Estes ML, McAllister AK. Immune mediators in the brain and peripheral
tissues in autism spectrum disorder. Nat Rev Neurosci. 2015;16:469–86.
11. Bilbo SD, Schwarz JM. The immune system and developmental programming
of brain and behavior. Front Neuroendocrinol. 2012;33:267–86.
12. Careaga M, Ashwood P. Autism spectrum disorders: from immunity to
behavior. In: Yan Q, editor. Psychoneuroimmunology, vol. 934. New York:
Humana Press; 2012. p. 219–40. Methods in Molecular Biology.
13. Di Marco B, Bonaccorso CM, Aloisi E, D'Antoni S, Catania MV. Neuro-
inflammatory mechanisms in developmental disorders associated with
intellectual disability and autism spectrum disorder: a neuro-immune
perspective. CNS Neurol Disord Drug Targets. 2016;15(4):448–463.
14. Chess S, Fernandez P, Korn S. Behavioral consequences of congenital
rubella. J Pediatr. 1978;93:699–703.
15. Atladóttir HÓ, Pedersen MG, Thorsen P, Mortensen PB, Deleuran B, Eaton
WW, Parner ET. Association of family history of autoimmune diseases and
autism spectrum disorders. Pediatrics. 2009;124:687–94.
16. Comi AM, Zimmerman AW, Frye VH, Law PA, Peeden JN. Familial clustering
of autoimmune disorders and evaluation of medical risk factors in autism.
J Child Neurol. 1999;14:388–94.
17. Herbert MR, Russo J, Yang S, Roohi J, Blaxill M, Kahler S, Cremer L, Hatchwell
E. Autism and environmental genomics. Neurotoxicology. 2006;27:671–84.
18. Mostafa GA, Al Shehab A, Fouad NR. Frequency of CD4+ CD25high
regulatory T cells in the peripheral blood of Egyptian children with autism.
J Child Neurol. 2010;25:328–35.
19. Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah IN, Van de
Water J. Altered T cell responses in children with autism. Brain Behav
Immun. 2011;25:840–9.
20. Ashwood P, Corbett BA, Kantor A, Schulman H, Van de Water J, Amaral DG.
In search of cellular immunophenotypes in the blood of children with
autism. PLoS One. 2011;6:e19299.
21. Boyman O, Purton JF, Surh CD, Sprent J. Cytokines and T-cell homeostasis.
Curr Opin Immunol. 2007;19:320–6.
22. Ransohoff RM. Chemokines and chemokine receptors: standing at the
crossroads of immunobiology and neurobiology. Immunity. 2009;31:711–21.
23. Ransohoff RM, Brown MA. Innate immunity in the central nervous system.
J Clin Invest. 2012;122:1164–71.
24. Whicher J, Evans S. Cytokines in disease. Clin Chem. 1990;36:1269–81.
25. Bade G, Khan MA, Srivastava AK, Khare P, Solaiappan KK, Guleria R, Palaniyar
N, Talwar A. Serum cytokine profiling and enrichment analysis reveal the
involvement of immunological and inflammatory pathways in stable
patients with chronic obstructive pulmonary disease. Int J Chron Obstruct
Pulmon Dis. 2014;9:759–73.
26. Valeyev NV, Hundhausen C, Umezawa Y, Kotov NV, Williams G, Clop A,
Ainali C, Ouzounis C, Tsoka S, Nestle FO. A systems model for immune cell
interactions unravels the mechanism of inflammation in human skin. PLoS
Comput Biol. 2010;6:e1001024.
27. Bhavnani SK, Victor S, Calhoun WJ, Busse WW, Bleecker E, Castro M, Ju H,
Pillai R, Oezguen N, Bellala G, Brasier AR. How cytokines co-occur across
asthma patients: from bipartite network analysis to a molecular-based
classification. J Biomed Inform. 2011;44 Suppl 1:S24–30.
28. Jiang NM, Tofail F, Moonah SN, Scharf RJ, Taniuchi M, Ma JZ, Hamadani JD,
Gurley ES, Houpt ER, Azziz-Baumgartner E, et al. Febrile illness and pro-
inflammatory cytokines are associated with lower neurodevelopmental
scores in Bangladeshi infants living in poverty. BMC Pediatr. 2014;14:50.
Pardo et al. Molecular Autism  (2017) 8:1 Page 12 of 14
29. Ong'echa JM, Davenport GC, Vulule JM, Hittner JB, Perkins DJ. Identification
of inflammatory biomarkers for pediatric malarial anemia severity using
novel statistical methods. Infect Immun. 2011;79:4674–80.
30. Yan J, Greer JM, McCombe PA. Prolonged elevation of cytokine levels after
human acute ischaemic stroke with evidence of individual variability.
J Neuroimmunol. 2012;246:78–84.
31. Ransohoff RM, Schafer D, Vincent A, Blachere NE, Bar-Or A. Neuroinflammation:
ways in which the Iimune system affects the brain. Neurotherapeutics. 2015;12:
896–909.
32. Masi A, Quintana D, Glozier N, Lloyd A, Hickie I, Guastella A. Cytokine aberrations
in autism spectrum disorder: a systematic review and meta-analysis. Mol
Psychiatry. 2014;20(4):440–446.
33. Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah I, Van de Water
J. Elevated plasma cytokines in autism spectrum disorders provide evidence
of immune dysfunction and are associated with impaired behavioral
outcome. Brain Behav Immun. 2011;25:40–5.
34. Ricci S, Businaro R, Ippoliti F, Lo Vasco VR, Massoni F, Onofri E, Troili GM,
Pontecorvi V, Morelli M, Rapp Ricciardi M, Archer T. Altered cytokine and
BDNF levels in autism spectrum disorder. Neurotox Res. 2013;24(4):491–501.
35. Tobiasova Z, van der Lingen KH, Scahill L, Leckman JF, Zhang Y, Chae W,
McCracken JT, McDougle CJ, Vitiello B, Tierney E, et al. Risperidone-related
improvement of irritability in children with autism is not associated with
changes in serum of epidermal growth factor and interleukin-13. J Child
Adolesc Psychopharmacol. 2011;21:555–64.
36. Napolioni V, Ober-Reynolds B, Szelinger S, Corneveaux JJ, Pawlowski T,
Ober-Reynolds S, Kirwan J, Persico AM, Melmed RD, Craig DW, et al. Plasma
cytokine profiling in sibling pairs discordant for autism spectrum disorder.
J Neuroinflammation. 2013;10:38.
37. Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA.
Neuroglial activation and neuroinflammation in the brain of patients with
autism. Ann Neurol. 2005;57:67–81.
38. American Psychiatric Association. Diagnostic and statistical manual of
mental disorders, DSM-IV-TR. Washington: American Psychiatric Publishing;
2000.
39. Rutter M, LeCouteur A, Lord C. Autism diagnostic interview-revised (ADI-R).
Los Angeles: Western Psychological Services; 2003.
40. Lord C, Rutter M, DiLavore PC, Risi S. Autism diagnostic observation
schedule (ADOS). Los Angeles: Western Psychological Services; 1999.
41. Rutter M, Bailey A, Lord C. The social communication questionnaire: manual.
Los Angeles: Western Psychological Services; 2003.
42. Chaturvedi AK, Kemp TJ, Pfeiffer RM, Biancotto A, Williams M, Munuo S,
Purdue MP, Hsing AW, Pinto L, McCoy JP, Hildesheim A. Evaluation of
multiplexed cytokine and inflammation marker measurements: a
methodologic study. Cancer Epidemiol Biomarkers Prev. 2011;20:1902–11.
43. Zhou X, Fragala MS, McElhaney JE, Kuchel GA. Conceptual and
methodological issues relevant to cytokine and inflammatory marker
measurements in clinical research. Curr Opin Clin Nutr Metab Care.
2010;13:541.
44. Sacktor N, Miyahara S, Evans S, Schifitto G, Cohen B, Haughey N, Drewes JL,
Graham D, Zink MC, Anderson C. Impact of minocycline on cerebrospinal
fluid markers of oxidative stress, neuronal injury, and inflammation in
HIV-seropositive individuals with cognitive impairment. J Neurovirol.
2014;20:620–6.
45. Pardo CA, Buckley A, Thurm A, Lee L-C, Azhagiri A, Neville DM, Swedo SE. A
pilot open-label trial of minocycline in patients with autism and regressive
features. J Neurodev Disord. 2013;5:1–9.
46. SAS Institute I. SAS. 93rd ed. Cary: SAS Institute, Inc; 2012.
47. Verbeke G, Molenberghs G. Linear mixed models for longitudinal data.
Springer Science & Business Media; 2009.
48. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical
and powerful approach to multiple testing. J R Stat Soc B Methodol. 1995;
57(1):289–300.
49. Thompson EJ. Proteins of the cerebrospinal fluid. Analysis and interpretation
in the idagnosis and treatment of neurological disease. London: Elsevier
Academic Press; 2005.
50. Reiber H. Dynamics of brain-derived proteins in cerebrospinal fluid. Clin
Chim Acta. 2001;310:173–86.
51. Bromander S, Anckarsater R, Kristiansson M, Blennow K, Zetterberg H,
Anckarsater H, Wass CE. Changes in serum and cerebrospinal fluid
cytokines in response to non-neurological surgery: an observational
study. J Neuroinflammation. 2012;9:242.
52. Li X, Chauhan A, Sheikh AM, Patil S, Chauhan V, Li X-M, Ji L, Brown T,
Malik M. Elevated immune response in the brain of autistic patients.
J Neuroimmunol. 2009;207:111–6.
53. Lubkowska A, Dolegowska B, Banfi G. Growth factor content in PRP and
their applicability in medicine. J Biol Regul Homeost Agents. 2012;26:3s–22s.
54. Wieduwilt MJ, Moasser MM. The epidermal growth factor receptor family:
biology driving targeted therapeutics. Cell Mol Life Sci. 2008;65:1566–84.
55. Aguirre A, Dupree JL, Mangin JM, Gallo V. A functional role for EGFR
signaling in myelination and remyelination. Nat Neurosci. 2007;10:990–1002.
56. Galvez-Contreras AY, Quinones-Hinojosa A, Gonzalez-Perez O. The role of EGFR
and ErbB family related proteins in the oligodendrocyte specification in
germinal niches of the adult mammalian brain. Front Cell Neurosci. 2013;7:258.
57. İşeri E, Güney E, Ceylan MF, Yücel A, Aral A, Bodur Ş, Şener Ş. Increased
serum levels of epidermal growth factor in children with autism. J Autism
Dev Disord. 2011;41:237–41.
58. Manzardo A, Henkhaus R, Dhillon S, Butler M. Plasma cytokine levels in
children with autistic disorder and unrelated siblings. Int J Dev Neurosci.
2012;30:121–7.
59. Onore C, Van de Water J, Ashwood P. Decreased levels of EGF in plasma of
children with autism spectrum disorder. Autism Research and Treatment.
2012;2012:4. http://dx.doi.org/10.1155/2012/205362.
60. Russo AJ. Decreased epidermal growth factor (EGF) associated with
HMGB1 and increased hyperactivity in children with autism. Biomark
Insights. 2013;8:35.
61. Urbich C, Dimmeler S. CD40 and vascular inflammation. Can J Cardiol. 2004;
20:681–3.
62. Cholette JM, Blumberg N, Phipps RP, McDermott MP, Gettings KF,
Lerner NB. Developmental changes in soluble CD40 ligand. J Pediatr.
2008;152:50–4. e51.
63. Butler MG, Hossain W, Sulsona C, Driscoll DJ, Manzardo AM. Increased
plasma chemokine levels in children with Prader–Willi syndrome. Am J Med
Genet A. 2015;167:563–71.
64. Buchhave P, Janciauskiene S, Zetterberg H, Blennow K, Minthon L, Hansson
O. Elevated plasma levels of soluble CD40 in incipient Alzheimer's disease.
Neurosci Lett. 2009;450:56–9.
65. Hope S, Hoseth E, Dieset I, Mørch RH, Aas M, Aukrust P, Djurovic S, Melle I,
Ueland T, Agartz I. Inflammatory markers are associated with general
cognitive abilities in schizophrenia and bipolar disorder patients and
healthy controls. Schizophr Res. 2015;165(2):188–194.
66. Toyoda T, Nakamura K, Yamada K, Thanseem I, Anitha A, Suda S, Tsujii M,
Iwayama Y, Hattori E, Toyota T, et al. SNP analyses of growth factor genes
EGF, TGFbeta-1, and HGF reveal haplotypic association of EGF with autism.
Biochem Biophys Res Commun. 2007;360:715–20.
67. Hardikar S, Song X, Kratz M, Anderson GL, Blount PL, Reid BJ, Vaughan
TL, White E. Intraindividual variability over time in plasma biomarkers of
inflammation and effects of long-term storage. Cancer Causes Control.
2014;25:969–76.
68. Epstein MM, Breen EC, Magpantay L, Detels R, Lepone L, Penugonda S,
Bream JH, Jacobson LP, Martinez-Maza O, Birmann BM. Temporal stability of
serum concentrations of cytokines and soluble receptors measured across
two years in low-risk HIV-seronegative men. Cancer Epidemiol Biomarkers
Prev. 2013;22:2009–15.
69. Mizutani M, Pino PA, Saederup N, Charo IF, Ransohoff RM, Cardona AE. The
fractalkine receptor but not CCR2 is present on microglia from embryonic
development throughout adulthood. J Immunol. 2012;188:29–36.
70. Cho SH, Sun B, Zhou Y, Kauppinen TM, Halabisky B, Wes P, Ransohoff RM,
Gan L. CX3CR1 protein signaling modulates microglial activation and
protects against plaque-independent cognitive deficits in a mouse model
of Alzheimer disease. J Biol Chem. 2011;286:32713–22.
71. Ransohoff RM, Liu L, Cardona AE. Chemokines and chemokine
receptors: multipurpose players in neuroinflammation. Int Rev
Neurobiol. 2007;82:187–204.
72. Pan W, Wu X, He Y, Hsuchou H, Huang EY-K, Mishra PK, Kastin AJ. Brain
interleukin-15 in neuroinflammation and behavior. Neurosci Biobehav Rev.
2013;37:184–92.
73. Gomez-Nicola D, Valle-Argos B, Pita-Thomas DW, Nieto-Sampedro M.
Interleukin 15 expression in the CNS: blockade of its activity prevents glial
activation after an inflammatory injury. Glia. 2008;56:494–505.
74. Gomez-Nicola D, Valle-Argos B, Pallas-Bazarra N, Nieto-Sampedro M.
Interleukin-15 regulates proliferation and self-renewal of adult neural stem
cells. Mol Biol Cell. 2011;22:1960–70.
Pardo et al. Molecular Autism  (2017) 8:1 Page 13 of 14
75. Michell-Robinson MA, Touil H, Healy LM, Owen DR, Durafourt BA, Bar-Or A,
Antel JP, Moore CS. Roles of microglia in brain development, tissue
maintenance and repair. Brain. 2015;138:1138–59.
76. Careaga M, Rogers S, Hansen RL, Amaral DG, Van de Water J, Ashwood P.
Immune endophenotypes in children with autism spectrum disorder. Biol
Psychiatry. 2015. http://dx.doi.org/10.1016/j.biopsych.2015.08.036.
77. Dada T, Rosenzweig JM, Al Shammary M, Firdaus W, Al Rebh S, Borbiev T,
Tekes A, Zhang J, Alqahtani E, Mori S. Mouse model of intrauterine
inflammation: sex-specific differences in long-term neurologic and immune
sequelae. Brain Behav Immun. 2014;38:142–50.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Pardo et al. Molecular Autism  (2017) 8:1 Page 14 of 14
